- Home
- OCGN vs RCKT Comparison
OCGN vs RCKT Comparison
Compare OCGN & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCGN
- RCKT
- Stock Information
- Founded
- OCGN 2013
- RCKT 1999
- Country
- OCGN United States
- RCKT United States
- Employees
- OCGN N/A
- RCKT N/A
- Industry
- OCGN Biotechnology: Biological Products (No Diagnostic Substances)
- RCKT Biotechnology: Pharmaceutical Preparations
- Sector
- OCGN Health Care
- RCKT Health Care
- Exchange
- OCGN Nasdaq
- RCKT Nasdaq
- Market Cap
- OCGN 321.7M
- RCKT 328.6M
- IPO Year
- OCGN N/A
- RCKT N/A
- Fundamental
- Price
- OCGN $1.39
- RCKT $3.08
- Analyst Decision
- OCGN Strong Buy
- RCKT Buy
- Analyst Count
- OCGN 3
- RCKT 13
- Target Price
- OCGN $6.00
- RCKT $12.96
- AVG Volume (30 Days)
- OCGN 2.6M
- RCKT 5.7M
- Earning Date
- OCGN 11-07-2025
- RCKT 11-06-2025
- Dividend Yield
- OCGN N/A
- RCKT N/A
- EPS Growth
- OCGN N/A
- RCKT N/A
- EPS
- OCGN N/A
- RCKT N/A
- Revenue
- OCGN $4,754,000.00
- RCKT N/A
- Revenue This Year
- OCGN N/A
- RCKT N/A
- Revenue Next Year
- OCGN N/A
- RCKT $108.43
- P/E Ratio
- OCGN N/A
- RCKT N/A
- Revenue Growth
- OCGN N/A
- RCKT N/A
- 52 Week Low
- OCGN $0.52
- RCKT $2.19
- 52 Week High
- OCGN $1.33
- RCKT $22.01
- Technical
- Relative Strength Index (RSI)
- OCGN 83.73
- RCKT 44.36
- Support Level
- OCGN $1.00
- RCKT $3.09
- Resistance Level
- OCGN $1.25
- RCKT $3.29
- Average True Range (ATR)
- OCGN 0.06
- RCKT 0.15
- MACD
- OCGN 0.04
- RCKT -0.03
- Stochastic Oscillator
- OCGN 92.69
- RCKT 12.20
About OCGN Ocugen Inc.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.